1) Sandrock A. Aducanumab for the treatment of Alzheimer's disease. 2020.11.6 US FDA advisory committee : https://www.fda.gov/advisory-committees/advisory-committee-calendar
2) Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019 ; 15 (2) : 73-88. PMID : 30610216
3) ロイター, アルツハイマー新薬承認のFDAに専門家から疑義の声 https://jp.reuters.com/article/alzheimer-fda-idJPKCN2DQ0E7
4) Public Citizen Health Research Group : Aducanumab https://www.citizen.org/article/aducanumab/
5) Public Citizen Health Research Group : Press Statement : FDA's Decision to Approve Aducanumab for Alzheimer's Disease Shows Reckless Disregard for Science, Severely Damages Agency's Credibility, June 7, 2021
6) Combined FDA and Applicant PCNS Drugs Advisory Committee Briefing Document https://www.fda.gov/media/143502/download
7) Times, Clinics Won't Provide It. Insurers Won't Cover It. So Will the First Alzheimer's Drug Make a Difference? https://time.com/6081333/biogen-alzheimers-drug-aduhelm-fdacontroversy/